Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria - PubMed
3 hours ago
- #dupilumab
- #chronic spontaneous urticaria
- #omalizumab
- Matching-adjusted indirect comparison analysis was used to compare omalizumab and dupilumab in chronic spontaneous urticaria patients.
- Omalizumab showed statistically significant greater improvements in disease activity (UAS7) and itch severity (ISS7) compared to dupilumab.
- The analysis utilized patient-level data from omalizumab trials (ASTERIA I/II) and aggregate data from dupilumab trial (LIBERTY-CSU CUPID Study A).
- At week 12, omalizumab versus placebo showed a UAS7 change of -12.6 and ISS7 change of -5.4, while dupilumab versus placebo showed -5.0 and -2.4 respectively.
- Despite limitations, the study concludes omalizumab is an effective treatment option for chronic spontaneous urticaria.